FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092080507> ?p ?o ?g. }

• W2092080507 endingPage "319" @default.
• W2092080507 startingPage "305" @default.
• W2092080507 abstract "Abstract. The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors or statins are the most successful cardiovascular drugs of all time. By interrupting cholesterol synthesis in the liver, they activate hepatocyte low‐density lipoprotein (LDL) receptors and produce consistent and predictable reductions in circulating LDL cholesterol with resulting reproducible improvements in cardiovascular risk by retarding or even regressing the march of atherosclerosis in all major arterial trees (coronary, cerebral and peripheral). Clinical trials have demonstrated their capacity not only to extend life, but also to improve its quality by retarding the progression of diabetes mellitus and chronic renal disease and by enhancing central and peripheral blood flow. They are amongst the most extensively investigated pharmaceutical agents in current clinical use. In cardiovascular end‐point trials they have proven ability to help prevent that first and all important myocardial infarction and to reduce the likelihood of a recurrence in those who do succumb. They are equally effective in men and women of all ages and at all levels of cardiovascular risk, whether caused by hypercholesterolaemia, hypertension, cigarette smoking, diabetes mellitus or the metabolic syndrome. In addition, they improve the outlook of patients with familial hypercholesterolaemia whose LDL receptor function is deficient or defective; and all of this comes at minimal risk to the recipient. Their most important potential side effect is myopathy, which on very rare occasions may lead to rhabdomyolysis. Clinical experience shows that myopathic symptoms with creatine kinase levels raised to more than 10 times the upper limit of normal is seen in <0.01% of recipients and progression to fatal rhabdomyolysis because of renal failure has been recorded in only 0.15 cases per million prescriptions. Liver function abnormalities are also, rarely, seen. Again, the frequency of raised aspartate or alanine aminotransferase to more than three times the normal limit is encountered in no more than 1–2% of all treated patients and is completely reversible upon withdrawal of treatment. Progression to hepatitis or liver failure does not occur. This constellation of benefits with little side effect penalty has resulted in the comparison of statins with antibiotics in the global battle against cardiovascular disease." @default.
• W2092080507 created "2016-06-24" @default.
• W2092080507 creator A5048047555 @default.
• W2092080507 date "2006-09-08" @default.
• W2092080507 modified "2023-10-16" @default.
• W2092080507 title "Who should receive a statin these days? Lessons from recent clinical trials" @default.
• W2092080507 cites W1485646988 @default.
• W2092080507 cites W155654176 @default.
• W2092080507 cites W1954373103 @default.
• W2092080507 cites W1964836458 @default.
• W2092080507 cites W1989432650 @default.
• W2092080507 cites W2005036362 @default.
• W2092080507 cites W2017612306 @default.
• W2092080507 cites W2018711158 @default.
• W2092080507 cites W2029989164 @default.
• W2092080507 cites W2031185570 @default.
• W2092080507 cites W2036773140 @default.
• W2092080507 cites W2096711488 @default.
• W2092080507 cites W2100800328 @default.
• W2092080507 cites W2104897071 @default.
• W2092080507 cites W2107295258 @default.
• W2092080507 cites W2109397913 @default.
• W2092080507 cites W2111763701 @default.
• W2092080507 cites W2111977341 @default.
• W2092080507 cites W2118418912 @default.
• W2092080507 cites W2129750583 @default.
• W2092080507 cites W2130636082 @default.
• W2092080507 cites W2133402021 @default.
• W2092080507 cites W2135631433 @default.
• W2092080507 cites W2139168645 @default.
• W2092080507 cites W2144160860 @default.
• W2092080507 cites W2155598961 @default.
• W2092080507 cites W2159449551 @default.
• W2092080507 cites W2160152341 @default.
• W2092080507 cites W2160390128 @default.
• W2092080507 cites W2165412221 @default.
• W2092080507 cites W2247997571 @default.
• W2092080507 cites W2341665659 @default.
• W2092080507 cites W2615845755 @default.
• W2092080507 cites W38523360 @default.
• W2092080507 cites W4231197286 @default.
• W2092080507 cites W4236582255 @default.
• W2092080507 cites W4238099401 @default.
• W2092080507 cites W4238251256 @default.
• W2092080507 cites W4240954959 @default.
• W2092080507 cites W424467158 @default.
• W2092080507 cites W4248021162 @default.
• W2092080507 cites W4254363271 @default.
• W2092080507 doi "https://doi.org/10.1111/j.1365-2796.2006.01700.x" @default.
• W2092080507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16961668" @default.
• W2092080507 hasPublicationYear "2006" @default.
• W2092080507 type Work @default.
• W2092080507 sameAs 2092080507 @default.
• W2092080507 citedByCount "44" @default.
• W2092080507 countsByYear W20920805072012 @default.
• W2092080507 countsByYear W20920805072013 @default.
• W2092080507 countsByYear W20920805072015 @default.
• W2092080507 countsByYear W20920805072016 @default.
• W2092080507 countsByYear W20920805072019 @default.
• W2092080507 crossrefType "journal-article" @default.
• W2092080507 hasAuthorship W2092080507A5048047555 @default.
• W2092080507 hasBestOaLocation W20920805071 @default.
• W2092080507 hasConcept C126322002 @default.
• W2092080507 hasConcept C127413603 @default.
• W2092080507 hasConcept C134018914 @default.
• W2092080507 hasConcept C164705383 @default.
• W2092080507 hasConcept C2776839432 @default.
• W2092080507 hasConcept C2777300911 @default.
• W2092080507 hasConcept C2777482532 @default.
• W2092080507 hasConcept C2778163477 @default.
• W2092080507 hasConcept C2779379848 @default.
• W2092080507 hasConcept C2780072125 @default.
• W2092080507 hasConcept C2780645631 @default.
• W2092080507 hasConcept C500558357 @default.
• W2092080507 hasConcept C535046627 @default.
• W2092080507 hasConcept C555293320 @default.
• W2092080507 hasConcept C71924100 @default.
• W2092080507 hasConcept C78519656 @default.
• W2092080507 hasConceptScore W2092080507C126322002 @default.
• W2092080507 hasConceptScore W2092080507C127413603 @default.
• W2092080507 hasConceptScore W2092080507C134018914 @default.
• W2092080507 hasConceptScore W2092080507C164705383 @default.
• W2092080507 hasConceptScore W2092080507C2776839432 @default.
• W2092080507 hasConceptScore W2092080507C2777300911 @default.
• W2092080507 hasConceptScore W2092080507C2777482532 @default.
• W2092080507 hasConceptScore W2092080507C2778163477 @default.
• W2092080507 hasConceptScore W2092080507C2779379848 @default.
• W2092080507 hasConceptScore W2092080507C2780072125 @default.
• W2092080507 hasConceptScore W2092080507C2780645631 @default.
• W2092080507 hasConceptScore W2092080507C500558357 @default.
• W2092080507 hasConceptScore W2092080507C535046627 @default.
• W2092080507 hasConceptScore W2092080507C555293320 @default.
• W2092080507 hasConceptScore W2092080507C71924100 @default.
• W2092080507 hasConceptScore W2092080507C78519656 @default.
• W2092080507 hasIssue "4" @default.
• W2092080507 hasLocation W20920805071 @default.
• W2092080507 hasLocation W20920805072 @default.
• W2092080507 hasOpenAccess W2092080507 @default.

• next